Le Lézard
Classified in: Health, Business
Subject: ACC

QIAGEN to Take Impairment on Deferred Tax Assets, Informs on Expected Impacts of New U.S. Tax Law and Other Changes in Global Tax Environment


GERMANTOWN, Maryland and HILDEN, Germany, December 22, 2017 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announces that, mainly as a consequence of the new U.S. tax legislation, it will take an after-tax charge on net income of approximately $110-120 million (or about $0.47-$0.52 per share) in the fourth quarter of 2017, and an additional after-tax charge in 2018 of approximately $7 million (or about $0.03 per share).

Click here for the full version of the press release:

https://corporate.qiagen.com/newsroom/press-releases/2017/20171222_US_Tax_Reform?sc_lang=en

Contacts:

QIAGEN
Investor Relations
John Gilardi
e-mail: [email protected]
+49-2103-29-11711
 
Public Relations    
Dr. Thomas Theuringer    
e-mail: [email protected]
+49-2103-29-11826

SOURCE Qiagen N.V.


These press releases may also interest you

at 02:45
ASE Technology Holding Co., Ltd. (TWSE: 3711, NYSE: ASX) ("We", "ASEH", or the "Company"), the leading provider of semiconductor assembly and testing services ("ATM") and the provider of electronic manufacturing services ("EMS"), today reported its...

at 02:39
MYTILINEOS Energy & Metals (RIC: MYTr.AT) (Bloomberg: MYTIL.GA) announces its Q1 2024 financial results. 10% increase in Net Profit after minorities to ?158 million vs. ?143 million in Q1 2023. Earnings per Share came in at ?1.141, an increase of...

at 02:30
Allied Market Research published a report, titled, "Pension Administration Software Market by Component (Solution and Services), Deployment Mode (On-Premise and Cloud), Type (Public Pension and Private Pension), End User (Employers, Pension Plan...

at 02:26
Having consistently outperformed its targets and strategic goals, MYTILINEOS Energy & Metals ("MYTILINEOS") has initiated a review and evaluation of its strategic options, in consultation with its financial, legal and tax...

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...



News published on and distributed by: